Thursday , November 14 2024
Home / SNB & CHF / Swiss pharma Novartis cleared of patent abuse allegations

Swiss pharma Novartis cleared of patent abuse allegations

Summary:
Competition Commission closes investigation against Novartis Keystone-SDA Listen to the article Listening the article Toggle language selector English (US)

Topics:
Swissinfo considers the following as important: , , ,

This could be interesting, too:

Frank Shostak writes Assumptions in Economics and in the Real World

Conor Sanderson writes The Betrayal of Free Speech: Elon Musk Buckles to Government Censorship, Again

Nachrichten Ticker - www.finanzen.ch writes Bitcoin erstmals über 80.000 US-Dollar

Nachrichten Ticker - www.finanzen.ch writes Kraken kündigt eigene Blockchain ‘Ink’ an – Neue Ära für den Krypto-Markt?

Swiss pharma Novartis cleared of patent abuse allegations
Competition Commission closes investigation against Novartis Keystone-SDA

A two-year investigation of alleged patent abuses by Swiss pharmaceutical company Novartis has been dropped by the Competition Commission (ComCo) without charges.

+ Get the most important news from Switzerland in your inbox

The investigations had shown that the Basel-based pharmaceutical company had acted in accordance with antitrust law, the authority announced on Thursday.

ComCo initiated the investigation in September 2022 and also carried out a search at the Novartis headquarters in Basel at the time. The pharmaceutical company had been accused of possibly using a patent for a preparation for the treatment of skin diseases in an unlawful manner to protect itself from competitors.

As part of the investigation, the Competition Commission cooperated with the European Commission.

The investigation has now revealed that Novartis’ conduct was common practice in the area of patent law and also complied with antitrust law, according to the press release. As the indications of abuse have not been confirmed, ComCo is closing the investigation without any consequences.

The European Commission has independently analysed the facts of the case and has come to the same conclusions, the Swiss authority continues.

Translated from German by DeepL/mga

This news story has been written and carefully fact-checked by an external editorial team. At SWI swissinfo.ch we select the most relevant news for an international audience and use automatic translation tools such as DeepL to translate it into English. Providing you with automatically translated news gives us the time to write more in-depth articles. You can find them here

If you want to know more about how we work, have a look here, and if you have feedback on this news story please write to [email protected].

Swiss pharma Novartis cleared of patent abuse allegations

More

GESDA takes a new step towards a global audience

This content was published on The Geneva Science and Diplomacy Anticipator (GESDA) is embarking on a new stage to confront the global public with the scientific challenges of the future.

Read more: GESDA takes a new step towards a global audience

Tags: ,
About Swissinfo
Swissinfo
SWI swissinfo.ch – the international service of the Swiss Broadcasting Corporation (SBC). Since 1999, swissinfo.ch has fulfilled the federal government’s mandate to distribute information about Switzerland internationally, supplementing the online offerings of the radio and television stations of the SBC. Today, the international service is directed above all at an international audience interested in Switzerland, as well as at Swiss citizens living abroad.

Leave a Reply

Your email address will not be published. Required fields are marked *